Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance

To the Editor:

We read with interest the research letter by JAVAID *et al.* [1] in a recent issue of the *European Respiratory Journal*. The authors aptly note some uncertainty in current World Health Organization (WHO) guidelines [2]. Nevertheless, we question the authors' main assertion that "high prevalence of ofloxacin resistance should not limit the applicability of the new shorter regimen". The shortened regimen has indeed produced promising results in a number of settings, albeit in populations carefully selected for their limited exposure and resistance to second-line drugs [3–5]. That this should be extended to settings with a high prevalence of fluoroquinolone resistance, without individual, rapid molecular testing for such resistance, is not supported by data or the WHO.

The present sub-national, cross-sectional study shows worryingly high levels of resistance to ofloxacin and other drugs contained in the shortened multidrug-resistant tuberculosis (MDR-TB) regimen. We concur with the authors on the importance of strengthening the public-health response to the various sources of fluoroquinolone-resistant tuberculosis in Pakistan. However, the presence of ofloxacin resistance in 48.6% of patients (tested at $2 \mu\text{g}\cdot\text{mL}^{-1}$) does not support the widespread applicability of the shortened regimen in this population. More than 50% of the patients in Bangladesh who had "high-level resistance" to ofloxacin based on this definition had unfavourable treatment outcomes on the shortened regimen [3]. Moreover, it is noteworthy that the present study does not report overlapping resistances among drugs to further inform estimates of the population eligible for the shortened regimen. Since rapid, reliable pyrazinamide testing is not routinely available, any use of the shortened regimen in the presence of high population levels of ofloxacin resistance needs to consider the frequency of concurrent pyrazinamide resistance. According to results from the meta-analyses that supported the development of the WHO recommendations, the probability of a favourable outcome on the shortened regimen is reduced from 90.3% (95% CI: 87.8–92.4%) among all patients to 67.9% (95% CI: 47.5–84.1%) among patients with isolates resistant to both drugs [6]. The author's assertion that "it is not recommended to base decision-making on the basis of resistance to pyrazinamide and ethambutol" is at odds with these findings and with WHO guidance. The latter recommends avoiding the shortened treatment in patients with "documented or likely resistance to medicines in the regimen" and "in patients infected with strains known or strongly suspected of being resistant to one or more drugs in the shorter MDR-TB treatment regimen (e.g. pyrazinamide)" [6].

The authors propose to increase the applicability of the shortened regimen in this and similar settings by: 1) increasing the clinical breakpoint for ofloxacin from 2 to $4 \mu\text{g}\cdot\text{mL}^{-1}$; 2) administering moxifloxacin at high dose; and 3) considering resistance to moxifloxacin/gatifloxacin, rather than ofloxacin, as an exclusion criterion for the short course treatment. However, these changes neither resolve the uncertainty in the guidelines nor strengthen the case for the shortened regimen in populations with a high prevalence of fluoroquinolone resistance. First, the rationale for the proposed increase in the minimum inhibitory concentration for ofloxacin, presumably intended to serve as a better proxy for resistance to later-generation fluoroquinolones, is not presented while this cut-off is higher than that used for both the national survey and the observational study that demonstrated the different clinical outcomes of the shorter regimen in strains with low-level *versus* high-level fluoroquinolone resistance [3, 7]. Secondly, moxifloxacin/gatifloxacin are already prescribed at high dose in some applications of the shortened

@ERSpublications

Shortened MDR-TB treatment requires individual, rapid resistance testing for fluoroquinolone resistance <http://ow.ly/sufM30cjQYM>

Cite this article as: Guglielmetti L, Varaine F, Huerga H, *et al.* Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance. *Eur Respir J* 2017; 50: 1700598 [<https://doi.org/10.1183/13993003.00598-2017>].

regimen (400–800 mg·day⁻¹ according to weight group), so the results showing reduced effectiveness in the presence of resistance to fluoroquinolones and pyrazinamide already factor in this reinforcement [6]. Thirdly, while we agree in principle that the usefulness of late-generation fluoroquinolones is best guided by susceptibility testing to these drugs, not by susceptibility testing to earlier-generation class members [8], the proposed modification to the guidance to rule out moxifloxacin/gatifloxacin resistance is problematic from an operational standpoint. Susceptibility testing for these drugs is infrequently available in high-burden settings (including Pakistan, according to the authors) and, more practically, rapid molecular tests will be used to assess eligibility. The careful interpretation of such tests, to identify individual patients eligible for the shortened regimen, will be especially important in settings with known high population levels of fluoroquinolone resistance. Existing data from sequencing suggest that resistances caused by mutations in the QRDR region of *gyrA* (except 94Ala) are associated with a significant increase in the level of poor outcomes on the shortened regimen [9]. Fortunately, there are other options and the advent of delamanid and bedaquiline [10], as well as other “core” MDR-TB drugs used in conventional regimens, offer alternatives to using the shortened regimen in patients in whom its success is likely to be compromised. Indeed, multiple new studies of shortened regimens containing these drugs (Nix-TB (NCT02333799), TB-PRACTECAL (NCT02589782), endTB (NCT02754765)) may generate palatable and effective alternatives.

In conclusion, we recommend caution in the introduction of the shortened MDR-TB regimen in settings with a high prevalence of resistance to ofloxacin or pyrazinamide. Eligibility for the shortened treatment should be evaluated individually according to rapid molecular testing and available drug susceptibility testing results.

Lorenzo Guglielmetti ^{1,2,3}, **Francis Varaine**¹, **Helena Huerga**⁴, **Maryline Bonnet**^{4,5}, **Michael L. Rich**⁶ and **Carole D. Mitnick**⁷

¹Médecins Sans Frontières, Paris, France. ²Laboratoire de Bactériologie-Hygiène, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Assistance Publique Hôpitaux de Paris, Paris, France. ³Team E13 (Bactériologie), Centre d'Immunologie et des Maladies Infectieuses (CIMI; INSERM U1135/UMRS CR7/CNRS ERL 8255), Faculté de Médecine Pierre et Marie Curie, Université Pierre et Marie Curie (UPMC; Université Paris 6), Sorbonne Universités, Paris, France. ⁴Epicentre, Paris, France. ⁵Institut de Recherche pour le Développement (INSERM), Université de Montpellier, Montpellier, France. ⁶Brigham and Women's Hospital, Boston, MA, USA. ⁷Harvard Medical School, Boston, MA, USA.

Correspondence: L. Guglielmetti, Faculté de Médecine Pierre et Marie Curie, Université Pierre et Marie Curie (UPMC; Université Paris 6), Sorbonne Universités, 91 Boulevard de l'hôpital, Paris 75634 CEDEX 13, France. E-mail: lorenzo.guglielmetti@gmail.com

Received: March 21 2017 | Accepted after revision: April 13 2017

Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

Acknowledgements: L. Guglielmetti, F. Varaine, H. Huerga, M. Bonnet, M.L. Rich and C.D. Mitnick contributed to the design of the manuscript. L. Guglielmetti, F. Varaine and C.D. Mitnick wrote the first draft and L. Guglielmetti, F. Varaine, H. Huerga, M. Bonnet, M.L. Rich and C.D. Mitnick reviewed and approved the manuscript for publication.

References

- 1 Javadi A, Ahmad N, Khan AH, *et al.* Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country. *Eur Respir J* 2017; 49: 1601967.
- 2 Varaine F, Guglielmetti L, Huerga H, *et al.* Eligibility for the shorter multidrug-resistant tuberculosis regimen: ambiguities in the World Health Organization recommendations. *Am J Respir Crit Care Med* 2016; 194: 1028–1029.
- 3 Aung KJ, Van Deun A, Declercq E, *et al.* Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. *Int J Tuberc Lung Dis* 2014; 18: 1180–1187.
- 4 Piubello A, Harouna SH, Souleymane MB, *et al.* High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. *Int J Tuberc Lung Dis* 2014; 18: 1188–1194.
- 5 Kuaban C, Noeske J, Rieder HL, *et al.* High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. *Int J Tuberc Lung Dis* 2015; 19: 517–524.
- 6 Falzon D, Schünemann HJ, Harausz E, *et al.* World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. *Eur Respir J* 2017; 49: 1602308.
- 7 Zignol M, Dean AS, Alikhanova N, *et al.* Population-based resistance of *Mycobacterium tuberculosis* isolates to pyrazinamide and fluoroquinolones: results from a multi-country surveillance project. *Lancet Infect Dis* 2016; 16: 1185–1192.
- 8 Farhat MR, Mitnick CD, Franke MF, *et al.* Concordance of *Mycobacterium tuberculosis* fluoroquinolone resistance testing: implications for treatment. *Int J Tuberc Lung Dis* 2015; 19: 339–341.
- 9 Rigouts L, Coeck N, Gumusboga M, *et al.* Specific *gyrA* gene mutations predict poor treatment outcome in MDR-TB. *J Antimicrob Chemother* 2016; 71: 314–323.
- 10 Borisov SE, Dheda K, Enwerem M, *et al.* Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. *Eur Respir J* 2017; 49: 1700387.